Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors

Journal of the American Society of Hypertension

Volumn 8, Issue 5, 2014, Pages 330-339

  Oliva, Raymond V ^a   Bakris, George L ^b  

^a PHILIPPINE GENERAL HOSPITAL   (Philippines)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Diabetes; glucose; hypertension; SGLT2; transporters

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLUCOSE; HYDROCHLOROTHIAZIDE; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; OSMOTIC DIURETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TOFOGLIFLOZIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ACTIVE TRANSPORT; BASOLATERAL MEMBRANE; BLOOD PRESSURE; DIABETIC PATIENT; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY; KIDNEY PROXIMAL TUBULE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSMOTIC DIURESIS; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM TRANSPORT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; DRUG EFFECTS; KIDNEY TUBULE ABSORPTION; METABOLISM; PHYSIOLOGY;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; RENAL REABSORPTION; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84901198078     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.02.003     Document Type: Review

References (44)

1. E.M. Wright, D.D. Loo, and B.A. Hirayama Biology of human sodium glucose transporters Physiol Rev 91 2011 733 794
2. M.A. Hediger, and D.B. Rhoads Molecular physiology of sodium-glucose cotransporters Physiol Rev 74 1994 993 1026
3. R.A. DeFronzo, M. Hompesch, S. Kasichayanula, X. Liu, Y. Hong, and M. Pfister et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes Diabetes Care 36 2013 3169 3176
4. J.E. Gerich Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 27 2010 136 142
5. D. Vasilakou, T. Karagiannis, E. Athanasiadou, M. Mainou, A. Liakos, and E. Bekiari et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann Int Med 159 2013 262 274
6. th ed. (2013) Available at http://www.merckmanuals.com/ home/heart-and-blood-vessel-disorders/high-blood-pressure/high-blood-pressure. html. Accessed September 3, 2013.
7. KDOQI KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease Am J Kidney Dis 49 2007 S12 S154
8. B.M.Y. Cheung, and C. Li Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep 14 2012 160 166
9. American Diabetes Association Standards of medical care in diabetes-2014 Diabetes Care 37 Suppl 1 2014 S14 S80
10. UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 854 865
11. Forxiga. Summary of product characteristics. Bristol-Myers Squibb/AstraZeneca EEIG. Available at http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002322/WC500136026.pdf. Accessed November 8, 2013.
12. Invokana (canagliflozin) tablets. FDA briefing document. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf. Accessed November 15, 2013.
13. J.P. Wilding, E. Ferrannini, V.A. Fonseca, W. Wilpshaar, P. Dhanjal, and A. Houzer Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study Diabetes Obes Metab 15 2013 403 409
14. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. Diabetologia 2013;56:S377 (Abstract number 942 presented as a platform presentation at the European Association for the Study of Diabetes (EASD) - 49th Annual Meeting; Barcelona, Spain; Sep 23-27 2013).
15. Hach T, Lambers Heerspink H, Pfar E, Lund S, Ley L, Broedl U, et al. The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes. Presented at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting. October 1-5, Berlin. Diabetologia 2012;55(supplement 1):page S317. [Abstract #770]. 2012.
16. J. Bolinder, O. Ljunggren, J. Kullberg, L. Johansson, J. Wilding, and A.M. Langkilde et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 97 2012 1020 1031
17. H.J. Lambers Heerspink, D. de Zeeuw, L. Wie, B. Leslie, and J. List Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes Diabetes Obes Metab 15 2013 853 862
18. R. Guthrie Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus Postgrad Med 125 2013 21 32
19. J.F. List, V. Woo, E. Morales, W. Tang, and F.T. Fiedorek Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 2009 650 657
20. E. Ferrannini, S.J. Ramos, A. Salsali, W. Tang, and J.F. List Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 33 2010 2217 2224
21. C.J. Bailey, J.L. Gross, A. Pieters, A. Bastien, and J.F. List Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 2223 2233
22. K. Kaku, S. Inoue, O. Matsuoka, A. Kiyosue, H. Azuma, and N. Hayashi et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 15 2013 432 440
23. C.J. Bailey, J.L. Gross, D. Hennicken, N. Iqbal, T.A. Mansfield, and J.F. List Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial BMC Med 11 2013 43
24. J.P. Wilding, P. Norwood, C. T'Joen, A. Bastien, J.F. List, and F.T. Fiedorek A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 32 2009 1656 1662
25. C.J. Bailey, N. Iqbal, C. T'Joen, and J.F. List Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range Diabetes Obes Metab 14 2012 951 959
26. J.P. Wilding, V. Woo, K. Rohwedder, J. Sugg, and S. Parikh Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years Diabetes Obes Metab 2013
27. R.R. Henry, A.V. Murray, M.H. Marmolejo, D. Hennicken, A. Ptaszynska, and J.F. List Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Int J Clin Pract 66 2012 446 456
28. K. Strojek, K.H. Yoon, V. Hruba, M. Elze, A.M. Langkilde, and S. Parikh Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 13 2011 928 938
29. J. Rosenstock, M. Vico, L. Wei, A. Salsali, and J.F. List Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 35 2012 1473 1478
30. M.A. Nauck, S. Del Prato, J.J. Meier, S. Duran-Garcia, K. Rohwedder, and M. Elze et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 34 2011 2015 2022
31. J.F. Yale, G. Bakris, B. Cariou, D. Yue, E. David-Neto, and L. Xi et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 2013 463 473
32. K. Stenlof, W.T. Cefalu, K.A. Kim, M. Alba, K. Usiskin, and C. Tong et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 15 2013 372 382
33. W.T. Cefalu, L.A. Leiter, K.H. Yoon, P. Arias, L. Niskanen, and J. Xie et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 2013 941 950
34. F.J. Lavalle-Gonzalez, A. Januszewicz, J. Davidson, C. Tong, R. Qiu, and W. Canovatchel et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 56 2013 2582 2592
35. G. Schernthaner, J.L. Gross, J. Rosenstock, M. Guarisco, M. Fu, and J. Yee et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 36 2013 2508 2515
36. J.P. Wilding, G. Charpentier, P. Hollander, G. Gonzalez-Galvez, C. Mathieu, and F. Vercruysse et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 67 2013 1267 1282
37. B. Bode, K. Stenlof, D. Sullivan, A. Fung, and K. Usiskin Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial Hosp Pract (1995) 41 2013 72 84
38. E. Ferrannini, L. Seman, E. Seewaldt-Becker, S. Hantel, S. Pinnetti, and H.J. Woerle A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes Metab 15 2013 721 728
39. J. Rosenstock, L.J. Seman, A. Jelaska, S. Hantel, S. Pinnetti, and T. Hach et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia Diabetes Obes Metab 15 2013 1154 1160
40. E. Ferrannini, A. Berk, S. Hantel, S. Pinnetti, T. Hach, and H.J. Woerle et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes Diabetes Care 36 2013 4015 4021
41. M. Roden, J. Weng, J. Eilbracht, B. Delafont, G. Kim, and H.J. Woerle et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Diabetes Endocrinol 1 2013 208 219
42. C.S. Kovacs, V. Seshiah, R. Swallow, R. Jones, H. Rattunde, and H.J. Woerle et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab 2013
43. H.U. Haring, L. Merker, E. Seewaldt-Becker, M. Weimer, T. Meinicke, and H.J. Woerle et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 36 2013 3396 3404
44. V.A. Fonseca, E. Ferrannini, J.P. Wilding, W. Wilpshaar, P. Dhanjal, and G. Ball et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus J Diabetes Complications 27 2013 268 273